Portopulmonary hypertension

Rodrigo Cartin-Ceba, Michael Joseph Krowka

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Portopulmonary hypertension (POPH) is a serious complication of portal hypertension that is associated with significant mortality. It is defined as the presence of pulmonary arterial hypertension in patients with documented portal hypertension. While pulmonary hypertension in liver disease can be due to a hyperdynamic (high-flow) state or increased pulmonary venous congestion (pulmonary venous hypertension), POPH develops because of vascular constriction or obstruction of the pulmonary arterial bed, manifesting as increased pulmonary vascular resistance. The reported incidence rates of POPH among liver transplant (LT) candidates range from 4.5 to 8.5 %. The severity of this condition is unrelated to the degree of portal hypertension or the etiology of liver disease. Intraoperative death and immediate post-LT mortality have occurred when LT is attempted in the setting of untreated, moderate-to-severe POPH. Transplantation is contraindicated unless the mean pulmonary artery pressure can be reduced to a safe level and right ventricular function is optimized. Screening for and accurately diagnosing POPH prior to LT has become the standard of care. Specific pulmonary artery vasodilator medications appear effective in reducing pulmonary artery pressures, improving right ventricular function and survival in uncontrolled studies from patients with POPH. The post-LT course of patients with moderate-to-severe POPH is unpredictable, but many patients can be weaned from pulmonary artery vasodilatory therapy over time.

Original languageEnglish (US)
Title of host publicationComplications of Cirrhosis: Evaluation and Management
PublisherSpringer International Publishing
Pages177-186
Number of pages10
ISBN (Print)9783319136141, 9783319136134
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hypertension
Pulmonary Artery
Transplants
Portal Hypertension
Pulmonary Hypertension
Liver
Right Ventricular Function
Liver Diseases
Pressure
Lung
Mortality
Hyperemia
Standard of Care
Vasodilator Agents
Constriction
Vascular Resistance
Blood Vessels
Transplantation
Survival
Incidence

Keywords

  • Cirrhosis
  • Liver transplant
  • Portal hypertension
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cartin-Ceba, R., & Krowka, M. J. (2015). Portopulmonary hypertension. In Complications of Cirrhosis: Evaluation and Management (pp. 177-186). Springer International Publishing. https://doi.org/10.1007/978-3-319-13614-1_19

Portopulmonary hypertension. / Cartin-Ceba, Rodrigo; Krowka, Michael Joseph.

Complications of Cirrhosis: Evaluation and Management. Springer International Publishing, 2015. p. 177-186.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cartin-Ceba, R & Krowka, MJ 2015, Portopulmonary hypertension. in Complications of Cirrhosis: Evaluation and Management. Springer International Publishing, pp. 177-186. https://doi.org/10.1007/978-3-319-13614-1_19
Cartin-Ceba R, Krowka MJ. Portopulmonary hypertension. In Complications of Cirrhosis: Evaluation and Management. Springer International Publishing. 2015. p. 177-186 https://doi.org/10.1007/978-3-319-13614-1_19
Cartin-Ceba, Rodrigo ; Krowka, Michael Joseph. / Portopulmonary hypertension. Complications of Cirrhosis: Evaluation and Management. Springer International Publishing, 2015. pp. 177-186
@inbook{83fc63217a6b4f70bf04cc6a8d5aeff1,
title = "Portopulmonary hypertension",
abstract = "Portopulmonary hypertension (POPH) is a serious complication of portal hypertension that is associated with significant mortality. It is defined as the presence of pulmonary arterial hypertension in patients with documented portal hypertension. While pulmonary hypertension in liver disease can be due to a hyperdynamic (high-flow) state or increased pulmonary venous congestion (pulmonary venous hypertension), POPH develops because of vascular constriction or obstruction of the pulmonary arterial bed, manifesting as increased pulmonary vascular resistance. The reported incidence rates of POPH among liver transplant (LT) candidates range from 4.5 to 8.5 {\%}. The severity of this condition is unrelated to the degree of portal hypertension or the etiology of liver disease. Intraoperative death and immediate post-LT mortality have occurred when LT is attempted in the setting of untreated, moderate-to-severe POPH. Transplantation is contraindicated unless the mean pulmonary artery pressure can be reduced to a safe level and right ventricular function is optimized. Screening for and accurately diagnosing POPH prior to LT has become the standard of care. Specific pulmonary artery vasodilator medications appear effective in reducing pulmonary artery pressures, improving right ventricular function and survival in uncontrolled studies from patients with POPH. The post-LT course of patients with moderate-to-severe POPH is unpredictable, but many patients can be weaned from pulmonary artery vasodilatory therapy over time.",
keywords = "Cirrhosis, Liver transplant, Portal hypertension, Pulmonary arterial hypertension",
author = "Rodrigo Cartin-Ceba and Krowka, {Michael Joseph}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-13614-1_19",
language = "English (US)",
isbn = "9783319136141",
pages = "177--186",
booktitle = "Complications of Cirrhosis: Evaluation and Management",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Portopulmonary hypertension

AU - Cartin-Ceba, Rodrigo

AU - Krowka, Michael Joseph

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Portopulmonary hypertension (POPH) is a serious complication of portal hypertension that is associated with significant mortality. It is defined as the presence of pulmonary arterial hypertension in patients with documented portal hypertension. While pulmonary hypertension in liver disease can be due to a hyperdynamic (high-flow) state or increased pulmonary venous congestion (pulmonary venous hypertension), POPH develops because of vascular constriction or obstruction of the pulmonary arterial bed, manifesting as increased pulmonary vascular resistance. The reported incidence rates of POPH among liver transplant (LT) candidates range from 4.5 to 8.5 %. The severity of this condition is unrelated to the degree of portal hypertension or the etiology of liver disease. Intraoperative death and immediate post-LT mortality have occurred when LT is attempted in the setting of untreated, moderate-to-severe POPH. Transplantation is contraindicated unless the mean pulmonary artery pressure can be reduced to a safe level and right ventricular function is optimized. Screening for and accurately diagnosing POPH prior to LT has become the standard of care. Specific pulmonary artery vasodilator medications appear effective in reducing pulmonary artery pressures, improving right ventricular function and survival in uncontrolled studies from patients with POPH. The post-LT course of patients with moderate-to-severe POPH is unpredictable, but many patients can be weaned from pulmonary artery vasodilatory therapy over time.

AB - Portopulmonary hypertension (POPH) is a serious complication of portal hypertension that is associated with significant mortality. It is defined as the presence of pulmonary arterial hypertension in patients with documented portal hypertension. While pulmonary hypertension in liver disease can be due to a hyperdynamic (high-flow) state or increased pulmonary venous congestion (pulmonary venous hypertension), POPH develops because of vascular constriction or obstruction of the pulmonary arterial bed, manifesting as increased pulmonary vascular resistance. The reported incidence rates of POPH among liver transplant (LT) candidates range from 4.5 to 8.5 %. The severity of this condition is unrelated to the degree of portal hypertension or the etiology of liver disease. Intraoperative death and immediate post-LT mortality have occurred when LT is attempted in the setting of untreated, moderate-to-severe POPH. Transplantation is contraindicated unless the mean pulmonary artery pressure can be reduced to a safe level and right ventricular function is optimized. Screening for and accurately diagnosing POPH prior to LT has become the standard of care. Specific pulmonary artery vasodilator medications appear effective in reducing pulmonary artery pressures, improving right ventricular function and survival in uncontrolled studies from patients with POPH. The post-LT course of patients with moderate-to-severe POPH is unpredictable, but many patients can be weaned from pulmonary artery vasodilatory therapy over time.

KW - Cirrhosis

KW - Liver transplant

KW - Portal hypertension

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=84944608030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944608030&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-13614-1_19

DO - 10.1007/978-3-319-13614-1_19

M3 - Chapter

SN - 9783319136141

SN - 9783319136134

SP - 177

EP - 186

BT - Complications of Cirrhosis: Evaluation and Management

PB - Springer International Publishing

ER -